As infectious diseases spread or re-emerge in various parts of the world, travelers face an elevated risk of exposure to these pathogens during their journeys. Travelers may come into contact with infectious agents through interactions with local populations, contaminated food or water, insect bites, or exposure to environmental hazards. The heightened risk of infection underscores the importance of vaccination as a preventive measure to protect travelers from potentially serious or life-threatening diseases.
Outbreaks of infectious diseases, such as dengue fever, measles, Zika virus, and influenza, can have a significant impact on travel patterns and public health. Travelers may alter their travel plans or cancel trips to destinations affected by outbreaks, resulting in economic losses for the travel industry. In response to outbreaks, health authorities may recommend or mandate vaccination for travelers to affected areas to prevent the further spread of the disease. The occurrence of outbreaks and epidemics drives demand for travel vaccines as travelers seek protection against these infectious threats.
The rising incidence of infectious diseases drives the growth of the travel vaccine market by increasing the risk to travelers, prompting mandatory vaccination requirements, responding to outbreaks and epidemics, promoting preventive measures for endemic diseases, and addressing global health security concerns. Travel vaccines play a crucial role in protecting travelers from infectious threats and mitigating the spread of diseases within and across borders.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-travel-vaccine-market
Data Bridge Market Research analyzes that the Global Travel Vaccine Market is expected to reach USD 13.09 billion by 2032 from USD 6.14 billion in 2023, growing at a substantial CAGR of 8.9% in the forecast period of 2024 to 2032.
Key Findings of the Study
Government Regulations and Recommendations Regarding Vaccination
Many countries have implemented mandatory vaccination requirements for travelers entering their borders. These requirements are often based on the prevalence of certain diseases in specific regions and aim to avert the importation and spread of infectious diseases. For example, countries in Africa and South America may require proof of yellow fever vaccination for travelers arriving from regions where the disease is endemic. Such mandates create a direct demand for travel vaccines among travelers who need to comply with entry regulations.
Governments and health organizations often conduct public health campaigns to advance awareness about the importance of vaccination for travelers. These campaigns may target specific demographics or focus on diseases prevalent in popular tourist destinations. By educating the public about the risks associated with travel-related diseases and the preventive measures available, governments stimulate demand for travel vaccines among travelers.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2032
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Composition (Combination Vaccines and Mono Vaccines), Type (Inactivated Vaccines, Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, DNA Vaccines, and Viral Vector Vaccines), Category (Recommended Vaccine, Routine Vaccine, and Required Vaccine), Disease (Typhoid, Hepatitis, Cholera, Varicella, Influenza, Japanese Encephalitis, Meningococcal Meningitis, Yellow Fever, Rabies, DPT, Measles and Mumps, Tick-Borne Encephalitis, Malaria, Covid-19, Polio, and Others), Route of Administration (Injectable and Oral), Gender (Male and Female), Patient Type (Adult, Pediatric, and Geriatric), Age Group (20-50 Years, Less than 20 Years, and Above 50 Years), Distribution Channel (B2B and B2C)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Poland, Norway, Hungary, Austria, Ireland, Lithuania, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, Kuwait, and Rest of Middle East and Africa
|
|
Market Players Covered
|
GSK plc (U.K.), Bavarian Nordic (Denmark), Pfizer Inc. (U.S.), Abbott (U.S.), CSL (Australia), AstraZeneca (U.K.), Sanofi (France), Merck & Co., Inc. (U.S.), Valneva SE (France), Johnson & Johnson Services Inc. (U.S.), Dynavax Technologies. (U.S.), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis
The global travel vaccine market is segmented into nine notable segments which are based on composition, type, category, disease, route of administration, gender, patient type, age group, and distribution channel.
- Based on composition, the global travel vaccine market is segmented into combination vaccines and mono vaccines
In 2024, the combination vaccines segment is expected to dominate the Global Travel Vaccine Market
In 2024, the combination vaccines segment is expected to dominate the market with a market share of 69.29% due to the higher efficiency and easy availability.
- Based on type, the global travel vaccine market is segmented into inactivated vaccines, subunit, recombinant, polysaccharide and conjugate vaccines, live-attenuated vaccines, toxoid vaccines, DNA vaccines and viral vector vaccines
In 2024, the inactivated vaccines segment is expected to dominate the Global Travel Vaccine Market
In 2024, the inactivated vaccines is expected to dominate the market with a market share of 29.69% due to the growing emphasis on preventive healthcare and wellness.
- Based on category, the global travel vaccine market is segmented into recommended vaccine, routine vaccine and required vaccine. In 2024, the recommended vaccine segment is expected to dominate the market with a market share of 47.74%
- Based on diseases, the global travel vaccine market is segmented into typhoid, hepatitis, cholera, varicella, influenza, Japanese encephalitis, meningococcal meningitis, yellow fever, rabies, DPT, measles and mumps, tick-borne encephalitis, malaria, COVID-19, polio and others. In 2024, the typhoid segment is expected to dominate the market with a market share of 18.24%
- Based on route of administration, the global travel vaccine market is segmented into injectable and oral. In 2024, the injectable segment is expected to dominate the market with a market share of 82.14%
- Based on gender, the global travel vaccine market is segmented into male and female. In 2024, the male segment is expected to dominate the market with a market share of 53.43%
- Based on patient type, the global travel vaccine market is segmented into adult, pediatric and geriatric. In 2024, the adult segment is expected to dominate the market with a market share of 46.35%
- Based on age group, the global travel vaccine market is segmented into 20-50 years, less than 20 years and above 50 years. In 2024, the 20-50 years segment is expected to dominate the market with a market share of 50.73%
- Based on distribution channel, the global travel vaccine market is segmented into B2B and B2C. In 2024, the B2B segment is expected to dominate the market with a market share of 77.81%
Major Players
Data Bridge Market Research analyzes GSK plc (U.K.), Pfizer Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), and Johnson & Johnson Services Inc. (U.S.) as the major players operating in the global travel vaccine market.
Market Development
- In March 2024, Pfizer Inc. announced that the European Commission (EC) has granted marketing approval for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumonia in infants, children and adolescents from 6 weeks to less than 18 years of age
- In October 2023, GSK plc. announced that it has reached an exclusive agreement with Chongqing Zhifei Biological Products, Ltd. (Zhifei) to promote GSK's Zhifei vaccine in China for the first three years. Cooperation can be continued with the consent of all parties. Zhifei, China's largest vaccine company, has acquired innovative vaccines from China. By combining the scale and expertise of the two companies, the strategic partnership will significantly expand the availability of Shingrix, supporting rapid expansion of the vaccine to patients and future potential indications
- In October 2022, Merck & Co., Inc., known as MSD outside the United States and Canada, declared today that the European Commission (EC) has approved an expanded indication for VAXNEUVANCE (15-valent pneumococcal conjugate vaccine), which includes active immunization for prevention. For the treatment of invasive disease, pneumonia and acute otitis media affected by Streptococcus pneumoniae (S. pneumoniae) in infants, children and adolescents from 6 weeks to less than 18 years. The approval facilitates the availability of VAXNEUVANCE to this population in all 27 member states of the European Union (EU), as well as in Iceland, Norway and Liechtenstein
- In September 2022, AstraZeneca announces that doses of FLUMIST QUADRIVALENT (Influenza Vaccine Live, Intranasal) are now available in the United States for the 2022-2023 influenza season. FLUMIST QUADRIVALENT, the only Food and Drug Administration (FDA)-approved nasal spray influenza vaccine, is indicated for ages 2 to 49.1 years. According to the 2022-2023 recommendations of the Immunization Practices Advisory Committee (ACIP) from Centers for Disease Control and Prevention (CDC). And the American Academy of Pediatrics (AAP), FLUMIST QUADRIVALENT remains an alternative to flu vaccination in the United States this season. The CDC emphasizes that the most effective protection against seasonal flu is the annual flu vaccine. This approval will help the company to expand their business
- In February 2021, In February, Johnson & Johnson Services Inc. announced that the U.S. Food and Drug Administration (FDA) has delivered Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, established by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This has helped the company to strengthen its product portfolio
Geographical Analysis
Geographically, the countries covered in the global travel vaccine market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Poland, Norway, Hungary, Austria, Ireland, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, Kuwait, and rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is expected to be the dominant and fastest growing region in the Global Travel Vaccine Market
North America is expected to be the dominant and fastest growing region in the travel vaccine market due to its advancements in vaccine technology and government regulations and recommendations regarding vaccination.
For more detailed information about the Global Travel Vaccine Market report, click here – https://www.databridgemarketresearch.com/reports/global-travel-vaccine-market
